Despite FDA trial clearance, ibogaine metabolite won’t receive red carpet treatment

DemeRx is launching the first U.S. clinical trial of an ibogaine-derived drug candidate, marking a pivotal moment for a controversial psychedelic long sidelined by safety concerns.